RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $600
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $576 to $600.
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $576 to $600.